other material
confidence high
sentiment positive
materiality 0.50
Trevi Therapeutics regains Nasdaq minimum bid price compliance
Trevi Therapeutics, Inc.
- Received Nasdaq deficiency letter on Jan 10, 2022 for bid price below $1 for 30 consecutive days.
- Compliance regained after closing bid price above $1 for ten consecutive business days (March 2-15, 2022).
- Nasdaq notified company on March 16, 2022 that the matter is closed.
- Company's common stock remains listed on Nasdaq Global Market.